Intrapleural gene transfer of adenovirus-mediated interferon-alfa 2b in a preliminary study suggests the possibility that useful against pleural mesothelioma. Preliminary studies in small scale according to a study conducted by Dr.. Daniel H. Sterman. His research set security intrapleural delivery of adenovirus-mediated gene in patients with malignant mesothelioma may be used before getting treatment.
Results were published in the American Journal of Respiratory and Critical Care Medicine in June online, Dr. Sterman and colleagues from the University of Pennsylvania, Philadelphia, noted that the disease has a poor prognosis with current treatments. In previous studies they were able to induce local interferon concentrations were extremely high and prolonged, and tumor cell death, with a similar approach by using a vector of interferon-beta.
Gene transfer of interferon-alpha 2b given 3 patients with 2 doses for 3 days apart. This will increase levels of interferon-alpha is high in the pleura or systemically is clinically accompanied by flu-like symptoms. Six next patient, who received a lower dose, showed a decrease (but still significant) levels of interferon-alpha in pleural and serum levels of symptoms that can be tolerated. Giving expression vectors to extend the degree of interferon-alfa. Seven of the eight patients who were evaluated had an anti-humoral immune response against the tumor cells of mesothelioma. And although four subjects with advanced disease do not respond clinically, the five remaining patients had evidence of disease stability or regression. In fact, one providing a dramatic example of that is the partial regression of tumors at sites not adjacent to the infusion of vector.
Researchers concluded that the view of encouraging results, treatment regimen by incorporating immunogene multimodalitas will have an important role in the earliest stages of treatment for patients with malignant pleural mesothelioma.
No comments:
Post a Comment